Compare · NYMX vs ORKA
NYMX vs ORKA
Side-by-side comparison of Nymox Pharmaceutical Corporation (NYMX) and Oruka Therapeutics Inc. (ORKA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NYMX and ORKA operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- ORKA is the larger of the two at $4.89B, about 40.9x NYMX ($119.6M).
- ORKA has hit the wire 3 times in the past 4 weeks while NYMX has been quiet.
- ORKA has more recent analyst coverage (11 ratings vs 0 for NYMX).
- Company
- Nymox Pharmaceutical Corporation
- Oruka Therapeutics Inc.
- Price
- $0.20-19.60%
- $71.99-2.53%
- Market cap
- $119.6M
- $4.89B
- 1M return
- -
- -26.35%
- 1Y return
- -
- +162.07%
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- News (4w)
- 0
- 3
- Recent ratings
- 0
- 11
Nymox Pharmaceutical Corporation
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which has completed Phase III clinical trials for the treatment of benign prostatic hyperplasia, and Phase II clinical trials for low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. The company also develops and markets NicAlert and TobacAlert test strips that use urine or saliva to detect use of tobacco products. In addition, it offers AlzheimAlert, a proprietary urine assay that aids physicians in the diagnosis of Alzheimer's disease. The company was founded in 1989 and is headquartered in Nassau, The Bahamas.
Latest NYMX
- SEC Form 6-K filed by Nymox Pharmaceutical Corporation
- SEC Form 6-K filed by Nymox Pharmaceutical Corporation
- SEC Form 6-K filed by Nymox Pharmaceutical Corporation
- SEC Form 6-K filed by Nymox Pharmaceutical Corporation
- SEC Form 6-K filed by Nymox Pharmaceutical Corporation
- SEC Form 6-K filed by Nymox Pharmaceutical Corporation
- SEC Form 6-K filed by Nymox Pharmaceutical Corporation
- SEC Form 6-K filed by Nymox Pharmaceutical Corporation
- SEC Form 6-K filed by Nymox Pharmaceutical Corporation
- SEC Form 6-K filed by Nymox Pharmaceutical Corporation
Latest ORKA
- SEC Form 4 filed by Oruka Therapeutics Inc.
- SEC Form 4 filed by Oruka Therapeutics Inc.
- Chief Executive Officer Klein Lawrence Otto exercised 25,000 shares at a strike of $7.80 and sold $2,090,593 worth of shares (25,000 units at $83.62) as part of a pre-agreed trading plan (SEC Form 4)
- Oruka Therapeutics Announces Positive Week 28 Data for ORKA-001 from the Ongoing EVERLAST-A Trial Showing Deepening of Responses Without Additional Dosing
- Senior Vice President, Finance Agarwal Arjun sold $51,035 worth of shares (533 units at $95.75) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 14,219 units (SEC Form 4)
- General Counsel Quinlan Paul T exercised 10,000 shares at a strike of $7.80 and sold $936,417 worth of shares (10,000 units at $93.64) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Medical Officer Goncalves Joana exercised 7,000 shares at a strike of $7.32 and sold $734,145 worth of shares (7,947 units at $92.38) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 31,771 units (SEC Form 4) (for tax liability)
- Senior Vice President, Finance Agarwal Arjun sold $926,010 worth of shares (10,019 units at $92.43) as part of a pre-agreed trading plan and exercised 9,459 shares at a strike of $15.88, decreasing direct ownership by 4% to 14,752 units (SEC Form 4) (for tax liability)
- Chief Executive Officer Klein Lawrence Otto sold $234,681 worth of shares (2,452 units at $95.71), decreasing direct ownership by 0.26% to 923,128 units (SEC Form 4) to cover withholding tax
- General Counsel Quinlan Paul T sold $99,443 worth of shares (1,039 units at $95.71), decreasing direct ownership by 3% to 29,995 units (SEC Form 4) to cover withholding tax